Activated contact system and abnormal glycosaminoglycans in lupus and other auto- and non-autoimmune diseases

Progress in Molecular Biology and Translational Science

Volumn 93, Issue C, 2010, Pages 443-472

  Weiser, Peter ^a   Qian, Yi ^a   Pan, Jing ^a   Zhou, Xiaodong ^a   Lu, Hong ^a   Studelska, Daniel R ^a   Shih, Fei F ^a   Zhang, Lijuan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C1 inhibitor; C3a; C5a; Contact system; Glycosaminoglycan; Kallikrein; Kininogen; Osteoarthritis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; thrombin

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIGEN; GLYCOSAMINOGLYCAN; HEPARIN; THROMBIN;

ANIMAL; CHEMICALLY INDUCED DISORDER; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANIMALS; ANTICOAGULANTS; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; THROMBIN; THROMBOCYTOPENIA;

EID: 77958176288     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(10)93019-6     Document Type: Chapter

References (42)

1. A. Kavanaugh, R. Tomar, J. Reveille, D.H. Solomon, and H.A. Homburger Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists Arch Pathol Lab Med 124 2000 71 81
2. R. Lyons, S. Narain, C. Nichols, M. Satoh, and W.H. Reeves Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease Ann NY Acad Sci 1050 2005 217 228
3. E. Marshall Lupus: mysterious disease holds its secrets tight Science 296 2002 689 691
4. J.E. Salmon, G. Girardi, and E. Theodore Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation Trans Am Clin Climatol Assoc 118 2007 99 114
5. J.S. Levine, D.W. Branch, and J. Rauch The antiphospholipid syndrome N Engl J Med 346 2002 752 763
6. I. Martin-Toutain, J.C. Piette, M.C. Diemert, C. Faucher, L. Jobic, and A. Ankri High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia Lupus 16 2007 79 83
7. FDA Information on adverse event reports and heparin http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm112669.htm 2009
8. T.K. Kishimoto, K. Viswanathan, T. Ganguly, S. Elankumaran, S. Smith, and K. Pelzer Contaminated heparin associated with adverse clinical events and activation of the contact system N Engl J Med 358 2008 2457 2467 (Pubitemid 351793019)
9. A. Clark, A. Weymann, E. Hartman, Y. Turmelle, M. Carroll, and J.M. Thurman Evidence for non-traditional activation of complement factor C3 during murine liver regeneration Mol Immunol 45 2008 3125 3132
10. M. Huber-Lang, J.V. Sarma, F.S. Zetoune, D. Rittirsch, T.A. Neff, and S.R. McGuire Generation of C5a in the absence of C3: a new complement activation pathway Nat Med 12 2006 682 687
11. B.A. Waaler Contact activation in the intrinsic blood clotting system; studies on a plasma product formed on contact with glass and similar surfaces Scand J Clin Lab Invest 11 1959 1 133
12. R.W. Colman Contact activation (kallikreinkinin) pathway: multiple physiologic and pathophysiologic activities R.W. Colman, Hemostasis and Thrombosis 2006 Lippincott Williams & Wilkins Philadelphia
13. J. Pan, Y. Qian, X. Zhou, A. Pazandak, S.B. Frazier, and P. Weiser Oversulfated chondroitin sulfate is not the sole contaminant in heparin Nat Biotech 28 2010 203 207
14. J. Pan, Y. Qian, X. Zhou, A. Pazandak, S.B. Frazier, and P. Weiser Identification of chemically sulfated/desulfated glycosaminoglycans in contaminated heparins and development of a simple assay for the detection of most contaminants in heparin Glycobiol Insight 2 2010 1 12
15. Y. Qian, J. Plan, X. Zhou, P. Weiser, D. Hourcade, and K.M. Lizsewski Oversulfated heparinbyproducts induce thrombin generation through contact system activation Clin Appl ThrombHemos 16 2010 244 250
16. Y. Qian, J. Plan, X. Zhou, P. Weiser, H. Lu, and F.F. Shih Heparin andOversulfated heparin byproductinduce thrombin generation through contact system activation in plasma of patients with HIT Clin Appl Thromb Hemost 16 2010 251 260
17. J. Pan, Y. Qi, X. Zhou, H. Lu, E. Ramacciotti, and L. Zhang Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways J Biol Chem 2010 10.1074/jbc.M109.063735
18. R. Sasisekharan, R. Raman, and V. Prabhakar Glycomics approach to structurefunction relationships of glycosaminoglycans Annu Rev Biomed Eng 8 2006 181 231
19. J.H. Berden, R.M. Termaat, K. Brinkman, R.J. Smeenk, A.J. Swaak, and P. Faaber Binding of anti-DNA antibodies to glomerular heparan sulfate: a new clue for the pathogenesis of SLE nephritis? Nephrologie 10 1989 127 132
20. C.T. Ravirajan, L. Rowse, J.R. MacGowan, and D.A. Isenberg An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study Rheumatology (Oxford) 40 2001 1405 1412
21. J.Y. Wang, and M.H. Roehrl Glycosaminoglycans are a potential cause of rheumatoid arthritis Proc Natl Acad Sci USA 99 2002 14362 14367
22. D.R. Studelska, K. Giljum, L.M. McDowell, and L. Zhang Quantification of glycosaminoglycans by reversed-phase HPLC separation of fluorescent isoindole derivatives Glycobiology 16 2006 65 72
23. B.L. Zuraw, and J.G. Curd Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients J Clin Invest 78 1986 567 575
24. N.S. Jenny, R.L. Lundblad, and K.G. Mann Thrombin R.W. Colman, Hemostasis and thrombosis 2006 Lippincott Williams & Wilkins Philadelphia 193 213
25. T.W. Stief Kallikrein activates prothrombin Clin Appl Thromb Hemost 14 2008 97 98
26. T. Myles, T. Nishimura, T.H. Yun, M. Nagashima, J. Morser, and A.J. Patterson Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation J Biol Chem 278 2003 51059 51067
27. R.G. DiScipio The activation of the alternative pathway C3 convertase by human plasma kallikrein Immunology 45 1982 587 595
28. A. Saito Plasma kallikrein is activated on dermatan sulfate and cleaves factor H Biochem Biophys Res Commun 370 2008 646 650
29. I.M. Sainz, R.A. Pixley, and R.W. Colman Fifty years of research on the plasma kallikreinkinin system: from protein structure and function to cell biology and in vivo pathophysiology Thromb Haemost 98 2007 77 83
30. S.R. Coughlin Protease-activated receptors in hemostasis, thrombosis and vascular biology J Thromb Haemost 3 2005 1800 1814
31. D.B. Blossom, A.J. Kallen, P.R. Patel, A. Elward, L. Robinson, and G. Gao Outbreak of adverse reactions associated with contaminated heparin N Engl J Med 359 2008 2674 2684
32. F.F. Shih, and P.M. Allen T cells are not as degenerate as you think, once you get to know them Mol Immunol 40 2004 1041 1046
33. + T regulatory cells J Exp Med 199 2004 323 335
34. A.-S. Korganow, H. Ji, S. Mangialaio, V. Duchatelle, R. Pelanda, and T. Martin From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins Immunity 10 1999 451 461
35. D.R. Studelska, L. Mandik-Nayak, X. Zhou, J. Pan, P. Weiser, and L.M. McDowell High affinity glycosaminoglycan and autoantigen interaction explains joint specificity in a mouse model of rheumatoid arthritis J Biol Chem 284 2009 2354 2362
36. A. Greinacher, T. Kohlmann, U. Strobel, J.A. Sheppard, and T.E. Warkentin The temporal profile of the anti-PF4/heparin immune response Blood 113 2008 4970 4976
37. T.E. Warkentin, J.A. Sheppard, J.C. Moore, R.J. Cook, and J.G. Kelton Studies of the immune response in heparin-induced thrombocytopenia Blood 113 2009 4963 4969
38. G.F. Pineo, M.C. Brain, A.S. Gallus, J. Hirsh, M.W. Hatton, and E. Regoeczi Tumors, mucus production, and hypercoagulability Ann NY Acad Sci 230 1974 262 270
39. M.G. Wahrenbrock, and A. Varki Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"? Cancer Res 66 2006 2433 2441
40. E.N. Harris, J.A. Weigel, and P.H. Weigel The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin J Biol Chem 283 2008 17341 17350
41. E.N. Harris, S.V. Kyosseva, J.A. Weigel, and P.H. Weigel Expression, processing, and glycosaminoglycan binding activity of the recombinant HUMAN 315-kDa hyaluronic acid receptor for endocytosis (HARE) J Biol Chem 282 2007 2785 2797
42. I.R. Mackay, N.V. Leskovsek, and N.R. Rose Cell damage and autoimmunity: a critical appraisal J Autoimmun 30 2008 5 11